PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, is advancing through its development pipeline and prepares for clinical trials with CF102, the second drug candidate in its product pipeline. Can-Fite announced today that it submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to initiate phase I clinical trials with CF102. Can-Fite's second pipeline drug is intended for the treatment of liver diseases including liver cancer, hepatitis virus infections and liver regeneration. The combined market potential of drugs for these conditions is estimated at about USD 4 billion. Can-Fite estimates that the first clinical trial with CF102 will be initiated in early 2008, subject to FDA approval.
